This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
a medical device company dedicated to advancing ablation treatment for cardiac arrythmias, announced its participation at the HeartRhythm 2024 conference, taking place in person at the Boston Convention & Exhibition Center and virtually, May 16-19, 2024. milla1cf Wed, 05/15/2024 - 19:05 May 15, 2024 — CardioFocus, Inc. ,
Based on continuous monitoring of early recurrence of atrial tachyarrhythmia immediately after patients have undergone atrial fibrillation ablation, Musat et al. Early recurrence of atrial tachyarrhythmia (ERAT) is commonly seen following catheter ablation of AF, with reported incidences of up to 61% in the first three months.
The international, multi-center trial will provide clinical evaluation of Cortex's 510(k) cleared Ablamap System with electrographic flow (EGF) and newly released Ablacath Mapping Catheter basket mapping catheter to identify extra-pulmonary vein EGF sources.
Food and Drug Administration (FDA), has granted approval to Boston Scientific for its FARAPULSE Pulsed Field Ablation System. A company statement reported that its PFA System is indicated for the isolation of pulmonary veins in the treatment of drug-refractory, recurrent, symptomatic, paroxysmal (i.e.,
Outcomes of ablation with the FARAPULSE PFA System – a nonthermal treatment in which electric fields selectively ablateheart tissue – will be compared to outcomes following use of anti-arrhythmic drug (AAD) therapy, which is commonly prescribed for patients living with persistent AF. The company now anticipates U.S.
Titled "Real-world Data Affirms Safety and Effectiveness of Low/Zero Fluoroscopy Atrial Fibrillation Ablation," the study was presented as a late-breaker at the 29th Annual International AF Symposium. Biosense Webster's zero fluoroscopy workflow is the first and only such workflow available in a radiofrequency (RF) cardiac ablation device.
Late-breaking Clinical Trial Results from FARADISE, admIRE Study and Advent Trial at HeartRhythm 2024 Highlight Pulsed Field Ablation Developments for Atrial Fibrillation Treatment 8. Patent Covering the Use of Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF) 10.
Pulsed-field energy ablation (PFA) was significantly associated with hemolysis compared to radiofrequency ablation (RFA) following pulmonary vein isolation (PVI), according to the results of a study presented at HeartRhythm 2024.
Additionally, this platform integrates parameters such as contact force measurement and ablation indexes for RF and PFA which have proven in preclinical studies to be critical for lesion creation. With this differentiated system, Biosense Webster is giving EPs the tools and information they need in real-time.
During its Annual Conference, HRS 2024, the HeartRhythm Society (HRS) announced findings from three new studies demonstrating the safety and efficacy of pulsed field ablation (PFA), a nonthermal ablation treatment for patients with atrial fibrillation (AF).
1,2 People living with AFib face an increased risk of stroke, heart failure and death, and many rely on cardiac ablation to treat the condition effectively. The trial showed the Volt PFA System achieved pulmonary vein isolation (PVI) the method of destroying tissue causing a patient's AFib in 99.1% Procedural flexibility.
The VARIPULSE Platform is comprised of the VARIPULSE Catheter, a fully integrated variable-loop multielectrode catheter; the TRUPULSE Generator, a pulsed field ablation (PFA) generator; and the CARTO 3 System VARIPULSE Software, which provides full integration with the world's leading 3D cardiac mapping system.
Launching the first FDA -approved PFA technology is not just a milestone; the PulseSelect PFA system is setting a new standard in safety for AF ablation with excellent efficacy and efficiency 1. In my clinical experience with the catheter, it was designed for AF ablation procedures.
The combined solutions are expected to enhance performance and streamline workflows for electrophysiologists during catheter ablation procedures to treat atrial fibrillation , AFib. Our mission to combat complex heartrhythm diseases relies on optimizing interoperability. The company has obtained U.S.
a global leader in cardiac arrhythmia treatment and part of Johnson & Johnson MedTech , today announced European CE mark approval of the VARIPULSE Platform for the treatment of symptomatic drug refractory recurrent paroxysmal atrial fibrillation ( AF ) using pulsed field ablation (PFA). iii] The study reported a low fluoroscopy time of 7.8
MANIFEST-17K provides confidence that, unlike conventional thermal ablation, PFA with the pentaspline catheter does not cause the most feared complication of AF ablation—esophageal damage—nor does it cause pulmonary vein stenosis or persistent injury to the diaphragm,” says senior author Vivek Reddy, MD , The Leona M.
Scott Rankin 1 Associations Between Surgical Ablation and Operative Mortality After Mitral Valve Procedures The Annals of Thoracic Surgery June 2018 A. Chris Malaisrie Burden of preoperative atrial fibrillation in patients undergoing coronary artery bypass grafting The Journal of Thoracic and Cardiovascular Surgery June 2018 J.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content